好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

VNS therapy vs. discontinuation of VNS therapy: Long-term seizure outcome
Epilepsy/Clinical Neurophysiology (EEG)
P5 - Poster Session 5 (5:30 PM-6:30 PM)
6-028

Compare long-term seizure (sz) control in patients (pts) with continued vagal nerve stimulation (VNS) with those who discontinued VNS. 

Long term VNS follow-up (f/u) studies show progressive improvement but are limited by lack of comparison groups. This study compared long-term sz control in pts who continued VNS stimulation (“VNS-on”) to those who underwent VNS then discontinued treatment (“VNS-off”). Question: Do pts with long-term VNS have greater sz reduction than those who discontinue VNS?

Refractory epilepsy pts with VNS therapy for >3 yrs (and f/u >2 yrs after VNS discontinuation for VNS-off) with clear baseline (pre-VNS) and last f/u sz frequencies were included. Pts with brain surgery <3 yrs after VNS excluded; only last f/u prior to brain surgery, if performed, included. We assessed and compared 1) percent of pts with >50% sz reduction (50% responder rate), and 2) change in sz frequency at last f/u compared with baseline in VNS-on and VNS-off pts.

49 pts included: 33 VNS-on, 16 VNS-off. VNS-on pts had treatment for 116.6 ± 43 months. VNS-off pts had VNS treatment for 78 ± 37 months, discontinued treatment, then had 95.63 ± 38 months additional follow-up. 50% responder rates between groups (VNS-on: 54.5%; VNS-off: 50%, p=NS) were similar. However, VNS-on pts had significant reduction in sz frequency at last f/u compared with baseline (-12.7 sz/month± 34.1, p = 0.04) compared with VNS-off pts both right before VNS was discontinued (-2.8 sz/month ± 18.5, p = 0.55) and last f/u (-4.4 sz/month ± 14.7, p = 0.25), though effect size was small (0.28).

Pts with long-term VNS therapy and those who discontinued therapy had similar long-term 50% responder rates. However, pts with long-term VNS treatment may experience greater magnitude of sz reduction. Pts with poor VNS response may be more refractory. Larger confirmatory studies are needed.

Authors/Disclosures
Sonia Gill, MD (Inova Neurology)
PRESENTER
No disclosure on file
Hsiangkuo Yuan, MD, PhD (Jefferson Headache Center) An immediate family member of Dr. Yuan has received personal compensation for serving as an employee of Merck. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Yuan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Yuan has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Salvia. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cerenovous. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Regional Anesthesia and Pain Medicine. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Headache and Pain Reports. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Cephalalgia. The institution of Dr. Yuan has received research support from NIH. The institution of Dr. Yuan has received research support from American Headache Society. The institution of Dr. Yuan has received research support from Pfizer. Dr. Yuan has received publishing royalties from a publication relating to health care. Dr. Yuan has received publishing royalties from a publication relating to health care. Dr. Yuan has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with NIH. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving as a Invited speaker with Chinese Stroke Association.
Michael R. Sperling, MD, FAAN (Thomas Jefferson University) Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. The institution of Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medscape. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for International Medical Press. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Projects for Knowledge. The institution of Dr. Sperling has received research support from SK Life Science. The institution of Dr. Sperling has received research support from UCB Pharma . The institution of Dr. Sperling has received research support from Takeda. The institution of Dr. Sperling has received research support from Neurelis. The institution of Dr. Sperling has received research support from Engage Therapeutics . The institution of Dr. Sperling has received research support from Medtronic. The institution of Dr. Sperling has received research support from Cavion. The institution of Dr. Sperling has received research support from Xenon Pharma. The institution of Dr. Sperling has received research support from Cerevel. The institution of Dr. Sperling has received research support from National Institutes of Health . The institution of Dr. Sperling has received research support from DARPA. Dr. Sperling has received publishing royalties from a publication relating to health care. Dr. Sperling has received publishing royalties from a publication relating to health care. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Vice President with Epilepsy Consortium .
Scott Mintzer, MD (Thomas Jefferson Univ) No disclosure on file
Christopher Skidmore, MD (Thomas Jefferson University) Dr. Skidmore has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for SALTZ MONGELUZZI BENDESKY LLC. The institution of Dr. Skidmore has received research support from Neuropace. The institution of Dr. Skidmore has received research support from Jazz Pharmaceuticals. The institution of Dr. Skidmore has received research support from Rapport Therapeutics.
Maromi Nei, MD No disclosure on file